Rethinking Anti-CD20 Therapies: From Fixed to Precision Dosing

Denis Mulleman1, Katarina Vučićević2, James Bluett3

  • 1D. Mulleman, MD, PhD, Center for Molecular Biophysics, UPR CNRS 4301, Nanomedicines and Nanoprobes Department, University of Tours, and Department of Rheumatology, University Hospital Centre of Tours, Tours, France.

Summary

No abstract available in PubMed .